SRR934865
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 36.793692509855454
- age_years
- 39
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.549
- TGF_BETA_SIGNALING+0.444
- MYC_TARGETS_V2+0.377
- MITOTIC_SPINDLE+0.369
- INTERFERON_GAMMA_RESPONSE+0.362
- G2M_CHECKPOINT+0.337
- MYC_TARGETS_V1+0.334
- NOTCH_SIGNALING+0.325
- E2F_TARGETS+0.304
- WNT_BETA_CATENIN_SIGNALING+0.273
Top 10 suppressed
- SPERMATOGENESIS-0.340
- KRAS_SIGNALING_DN-0.320
- MYOGENESIS-0.287
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.244
- ESTROGEN_RESPONSE_LATE-0.206
- OXIDATIVE_PHOSPHORYLATION-0.193
- PANCREAS_BETA_CELLS-0.187
- COAGULATION-0.185
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.165
- XENOBIOTIC_METABOLISM-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934808 | — | — | 0.931 |
| 2 | E35A6AA5-331F-489B-8CE1-9D0BC4CDE119 | — | — | 0.927 |
| 3 | C67163A8-8A5F-4398-AC65-167218B010CF | — | — | 0.919 |
| 4 | EFB459E3-9B6A-4020-8556-6409065823B7 | — | — | 0.890 |
| 5 | SRR934763 | — | — | 0.885 |
| 6 | 15838786-D895-4F63-88A9-BDE627AE7958 | — | — | 0.882 |
| 7 | B2D8ED43-A698-4165-9A96-0ADEEFDA29ED | — | — | 0.881 |
| 8 | 9EE765BF-748F-41B9-926F-FFD0E8C079E3 | — | — | 0.879 |
| 9 | SRR934780 | — | — | 0.879 |
| 10 | SRR934775 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.549 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.444 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.377 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.369 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.362 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.337 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.334 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.325 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.304 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.273 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.255 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.246 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.224 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.213 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.209 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.185 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.147 | Inavolisib | — uncovered |
| COMPLEMENT | 0.145 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.124 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.108 | Idelalisib | — uncovered |